CHM and clostridium difficile infection: To further corroborate the efficacy of VNA2-Tcd in treating pigs for CDI, we employed a gene therapy approach in which an adenovirus vector (Ad/VNA2-Tcd) was administered that could promote the in vivo expression and secretion of VNA2-Tcd into the serum of treated pigs.